Recurrent Glioblastoma Clinical Trials in New York, New York

4 studies are recruiting for recurrent glioblastoma in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

   The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also impermeable to the passage of therapeutic molecules from the bloo…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Weill Cornell Medicine, New York, New York

   Locations

   56 in total

   Run by

   CarThera

   See if you can join NCT05902169 on ClinicalTrials.gov

2. A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

   The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Lenox Hill Hospital, New York, New York

   Locations

   9 in total

   Run by

   Boston Scientific Corporation

   See if you can join NCT05303467 on ClinicalTrials.gov

3. Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma

   A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for the treatment of recurrent Glioblastoma

   Stage

   Not phased

   Ages

   18 to 85

   Site

   NYU Langone Health, New York, New York

   Locations

   3 in total

   Run by

   Alpha Tau Medical LTD.

   See if you can join NCT06910306 on ClinicalTrials.gov

4. Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

   The purpose of this study is to find out how much tratuzumab deruxtecan (T-DXd) can penetrate the tumor when injected into the body, and whether T-DXd may be an effective treatment for brain cancers that express the HER2 protein.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06058988 on ClinicalTrials.gov